Phase IIA Trial of 1% Topical Cidofovir for Treatment of High-Grade Perianal Squamous Intraepithelial Neoplasia in HIV-Infected Men and Women (AMC046) by Stier, Elizabeth A. et al.
Boston University
OpenBU http://open.bu.edu
Department of Obstetrics and Gynecology MED: Obstetrics and Gynecology Papers
2010-10-11
Phase IIA Trial of 1% Topical
Cidofovir for Treatment of
High-Grade Perianal Squamous
Intraepithelial Neoplasia in
HIV-Infected Men and Women
(AMC046)
Stier, Elizabeth A, Stephen E Goldstone, Mark H Einstein, Naomi Jay, J Michael Berry,
Timothy Wilkin, Jeannette Lee, Lori Panther, David Aboulafia, Joel Palefsky. "Phase
IIA trial of 1% topical cidofovir for treatment of high-grade perianal squamous
intraepithelial neoplasia in HIV-infected men and women (AMC046)" Infectious
Agents and Cancer 5(Suppl 1):A60. (2010)
https://hdl.handle.net/2144/3408
Boston University
MEETING ABSTRACTS Open Access
Phase IIA trial of 1% topical cidofovir for
treatment of high-grade perianal squamous
intraepithelial neoplasia in HIV-infected men and
women (AMC046)
Elizabeth A Stier1*, Stephen E Goldstone2, Mark H Einstein3, Naomi Jay4, J Michael Berry4, Timothy Wilkin5,
Jeannette Lee6, Lori Panther7, David Aboulafia8, Joel Palefsky4
From 12th International Conference on Malignancies in AIDS and Other Acquired Immunodeficiencies
(ICMAOI)
Bethesda, MD, USA. 26-27 April, 2010
Objective
Treatments for high-grade perianal intraepithelial neo-
plasia (PAIN 2-3), include surgical ablation/excision and
have significant morbidity and recurrence rates. Cidofo-
vir, a cytidine nucleotide analogue, has broad-spectrum
antiviral activity. This multicenter study prospectively
evaluated the efficacy, safety, and tolerability of topical
cidofovir for treatment of PAIN 2-3 in HIV-positive
individuals.
Methods
HIV-positive patients with biopsy-proven PAIN 2-3 ≥ 3
cm2 were eligible. Subjects applied 1% topical cidofovir
for 6 two-week cycles consisting of 5 consecutive days
of treatment and 9 days without treatment. Subjects
were evaluated every 2 weeks. High-resolution anoscopy
and biopsy were performed 6 weeks after the last cycle.
Results were scored as stable disease (SD), partial
response (PR) (> 50% reduction in size), complete
response (CR), or progressive disease (PD) based on size
and histology.
Results
24 men and 9 women were enrolled. Mean age was
33 years, median HIV RNA level was <75 copies/ml,
and mean CD4 count was 440/µl. HPV DNA was
detected in intra-anal swabs of 31 of 32 (97%) subjects
with analyzable specimens. The most common type was
HPV16 (44%).
27 (82%) subjects completed treatment per protocol—
CR: 4 (15%); PR: 12 (44%); SD: 9 (33%); PD: 2 (7%) (1
with a superficially invasive cancer and 1 with new
PAIN 2-3). Six subjects did not complete treatment
because of discomfort (1), poor compliance (4), and CR
after 4 cycles (1).
26 of 33 subjects (79%) reported adverse events likely
related to treatment. Most were mild or moderate,
including self-limited, localized, superficial ulcerations in
the disease area (2 mild, 19 moderate, 1 severe), discom-
fort (4 mild, 14 moderate), itching (1 mild, 3 moderate),
and bleeding (6 mild). Seven (21%) had mild transient
proteinuria.
Conclusions
Topical cidofovir is a well-tolerated and effective treat-
ment for PAIN 2-3 in HIV-positive patients. A larger
study is warranted.
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